Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Microbiol Spectr. 2022 Apr 27;10(2):e0041122. doi: 10.1128/spectrum.00411-22. Epub 2022 Mar 29.
Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against Staphylococcus aureus biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm. Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics.
细菌生物膜很难消除,并且会在组织和医疗设备上形成,从而使许多感染变得复杂。噬菌体+抗生素组合(PAC)在生物膜上的活性可能比单独使用任何一种药物都要高,但很难预测哪种 PAC 方案会可靠有效。为了建立一种筛选金黄色葡萄球菌生物膜噬菌体+抗生素组合的方法,我们使用噬菌体 Sb-1 与临床相关抗生素的各种组合进行了生物膜时间杀伤分析(TKA)。我们确定了 PAC 对生物膜与浮游菌的活性,并研究了在暴露于 PAC(24 小时)期间出现的耐药性。正如预期的那样,针对生物膜的治疗方案比针对浮游菌的治疗方案少。在同基因菌株对的实验中,我们也发现 PAC 对 DNS-VISA 突变体的活性低于其各自的亲本。针对生物膜和浮游菌最有效的治疗方法是噬菌体+达托霉素+头孢洛林方案,该方案符合我们杀菌活性的严格定义(减少>3 对数 CFU/mL)。对于 VISA-DNS 菌株 8015 和 DNS 菌株 684,我们在噬菌体+达托霉素方案中检测到 Sb-1 和 DAP 之间的抗生物膜协同作用(与最佳单药相比减少>2 对数 CFU/mL)。在所有测试菌株中,我们没有观察到任何细菌对抗生素的重新敏感性,但在暴露于 PAC 方案后,噬菌体的耐药性得到了避免。噬菌体释放的细菌膜泡的趋势要么不受各种治疗方案的影响,要么减少。有趣的是,某些生物膜实验中的噬菌体产量大于类似的浮游实验,这表明 Sb-1 可能在生物膜上更有效地繁殖。生物膜相关的多药耐药感染对抗生素治疗构成重大挑战。生物膜的细胞外多聚物基质阻碍了抗生素的扩散,促进了多药耐药群体的出现。一些噬菌体(噬菌体)可以穿过生物膜基质,降解它,并支持抗生素渗透。然而,人们对噬菌体及其宿主在生物膜环境中的相互作用以及不同噬菌体+抗生素组合(PACs)与细菌浮游状态相比如何影响生物膜知之甚少,尽管零散的数据表明噬菌体+抗生素协同作用在更类似于生物膜的条件下更容易发生。我们的结果表明,噬菌体 Sb-1 可以感染生物膜和浮游状态的 MRSA 菌株,并提出了值得进一步研究的 PAC 方案,作为抗生素的辅助手段。